Chennai, Jan. 26 -- Highlights: ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...
Lactated Ringers Injection Market to reach USD 2.9 Bn by 2036, driven by rising hospital admissions, increasing surgical ...
From GLP-1 injections to NAD+ infusions, Boston has become ground zero for the longevity obsession—where everyone from Back ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
GlobalData on MSN
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...
Morning Overview on MSN
Gene editing breakthrough could kill off daily cholesterol pills
For decades, high cholesterol has meant a lifetime of daily pills, repeat blood tests and constant reminders that the biggest ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
By Jaspreet Kalra and Dharamraj Dhutia MUMBAI, Jan 23 (Reuters) - The Reserve Bank of India on Friday unveiled measures to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results